Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy

Application of a liquid chromatography–tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice

(2011) Silpa Nuthalapati et al.   JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent

(2009) Amy W. Chun et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells

(2009) A Prasad et al.   ONCOGENE

Impact of Angiogenesis Inhibition by Sunitinib on Tumor Distribution of Temozolomide

(2008) Q. Zhou et al.   CLINICAL CANCER RESEARCH

Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors

(2008) Antonio Jimeno et al.   JOURNAL OF CLINICAL ONCOLOGY

Differential effect of sunitinib on the distribution of temozolomide in an orthotopic glioma model

(2008) Qingyu Zhou et al.   NEURO-ONCOLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Design, Synthesis, and Biological Evaluation of (E)-Styrylbenzylsulfones as Novel Anticancer Agents

(2007) M. V. Ramana Reddy et al.   JOURNAL OF MEDICINAL CHEMISTRY